Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone versus exposure and response prevention for tic disorders
NL-OMON38252Active, not recruiting
- Sponsor
- HagaZiekenhuis
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of risperidone in Tourette syndrome (TS) and chronic tic disorder (2 arms), sponsored by HagaZiekenhuis. Primary endpoint: Tic severity by Yale Global Tic Severity Scale. Started Apr 2011; status: active, not recruiting.
02
Drugs
risperidone
03
Conditions
Tourette syndrome (TS)chronic tic disorder
Beyond the preview
Go deeper on NL-OMON38252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38252.